Treatment Information

Back

Bladder Cancer treatment details. Biologic therapy.

University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Ann Arbor, MI
Treatments:Biologic therapyHospital:University of Michigan Comprehensive Cancer Center
Drugs:Journal:Link
Date:Nov 2013

Description:

Patients:
This phase 2 study involved 26 previously treated advanced urothelial carcinoma patients. The median patient age was 69 years and 77% were male.

Treatment:
Patients were treated with the biologic therapy agent called sunitinib, a tyrosine kinase inhibitor of the VEGF protein that interferes with tumor growth.

Toxicities:
There was one reported death due to urinary tract infection and subsequent septic shock, although this was considered to be not related to treatment. Grade 4 thrombocytopenia and fatigue were also reported.

Results:
The median overall survival was 10.5 months.

Support:
This study was supported by Pfizer, makers of sunitinib.

Correspondence: Dr. Maha Hussain; email: [email protected]



Back